These evolving requirements are fostering a digitally secure infrastructure, significantly elevating the demand for blockchain solutions in the healthcare sector GLP-1 Receptor Agonists Obesity Drugs Market Analysis GLP-1 receptor agonists, a class of drugs that mimic the glucagon-such as peptide-1 hormone, are increasingly recognized as powerful therapeutic options for obesity management due to their dual benefits in appetite regulation and blood glucose control, making them essential tools in both endocrinology and weight-loss medicine The accelerating demand for GLP-1 receptor agonists is primarily driven by the global surge in obesity and type 2 diabetes cases, strong clinical outcomes demonstrating significant weight reduction, and growing medical and consumer acceptance of pharmacological obesity treatment North America dominated the GLP-1 receptor agonists obesity drugs market with the largest revenue share of 55.56% in 2024, characterized by high obesity prevalence, favorable reimbursement policies, and early adoption of innovative therapies such as semaglutide and tirzepatide, with the U.S

The drug is widely adopted across 80+ countries, with nearly 65% of prescriptions focused on type 2 diabetes management and 35% on obesity-related applications
Honokiol attenuates diabetic nephropathy by targeting SIRT3 to suppress mitochondrial ROS-induced pyroptosis
[3] Persulfides are intermediates in the biosynthesis of iron-sulfur proteins [4] and are invoked as precursors to hydrogen sulfide, a biological signaling molecule
Although the definition of carnitine insufficiency in liver cirrhosis patients remains unclear, the symptoms of carnitine deficiency are thought to be muscle cramps, general fatigue, hepatic encephalopathy, and hyperammonemia in liver cirrhosis patients
The higher prevalence of muscle mass reduction in patients with cirrhotic cramps [6] also justifies this finding